🔗 Share this article Recent Drugs Celebrated as a 'Turning Point' in Treating Drug-Resistant Gonorrhoea The initial novel therapies for gonorrhoea in decades are being hailed as a "huge turning point" in the fight against superbug strains of the infection, according to researchers. A Global Challenge The sexually transmitted infection are on the rise globally, with estimates suggesting more than 82 million infections annually. Especially elevated rates are observed in the African continent and nations within the WHO's designated area, which encompasses China and Mongolia to New Zealand. Across England, cases have hit a record high, while figures across Europe in 2023 were three times higher compared to figures for 2014. “The approval of novel therapies for gonorrhoea is an important and timely development in the context of growing infection rates, increasing antimicrobial resistance and the very limited treatment choices at this time.” Public health authorities are deeply concerned about the rise in drug-resistant strains. The WHO has listed it as a "high-priority threat". Recent surveillance found that resistance to key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024. Recent Drugs Receive Authorization Zoliflodacin, alternatively called Nuzolvence, was approved by the American regulatory agency in mid-December for treating gonorrhoea. This infection can lead to serious health problems, including the inability to conceive. Experts hope that focused deployment of this new drug will help slow the development of resistance. Gepotidacin, developed by the drugmaker GSK, also received approval in the same week. This medication, which is employed against urinary tract infections, was demonstrated in studies to be successful in treating superbug versions of the gonorrhoea bacteria. A Novel Development Model Zoliflodacin was the result of a new, not-for-profit approach for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the drug firm its industry partner to see it through. “This approval marks a huge turning point in the treatment of multidrug-resistant gonorrhoea, which up to this point has been outpacing medical innovation.” Clinical Trial Data and Worldwide Availability As per data detailed in a prominent scientific publication, the new drug successfully treated over nine in ten of uncomplicated infections. This puts it on an similar efficacy with the existing first-line therapy, which involves an injection and a pill. The research enrolled nearly 1,000 volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US. As part of the agreement of its development partnership, GARDP has the rights to register and commercialise the drug in a wide range of regions with limited resources. Clinicians directly involved have voiced optimism. The availability of a one-pill regimen like this is seen as a "critical tool" for managing the epidemic. This is deemed essential to reduce the burden of the infection for individuals and to halt the transmission of untreatable gonorrhoea worldwide.